SNHG15 and Familial prostate cancer: Furthermore, SNHG15 enhances tumour development or drug resistance in glioblastoma multiforme, colorectal carcinoma, and prostate cancer through the SNHG15/CDK6/miR-627, SNHG15/miR-141/SIRT1/Wnt/β-catenin, SNHG15/miR-338-3p/FKBP1A, and SNHG15/miR-338-3p/FOS-RAB14 axes [14–17].